This Phase IB/II clinical trial will test the safety and efficacy of the experimental drug ITI-007 in older adults with dementia and in cognitively normal volunteers age 65 and older.
|Min Age||Max Age||Gender||Healthy Volunteers|
Accepts Healthy Volunteers
Participants with Dementia
This study will test the effects of an experimental drug, ITI-007, compared to a placebo in both cognitively normal older adults and those with dementia. Vital signs, ECG and clinical laboratory test results, and any adverse events will be assessed. ITI-007 targets multiple brain systems, including modulation of dopamine receptors and serotonin transporters. It is being tested as an alternative to existing antipsychotic drugs to treat dementia-related agitation, aggression, and sleep problems as well as schizophrenia and other psychiatric diseases.
|Map Marker||City||State||Status||Primary Contact|
Geolocation is 34.1425078, -118.255075
Intra-Cellular Therapies, Inc.
Kimberly Vanover, PhD